tickdelta
Sign in
Screener / SEC EDGAR /CIK 0001478242 /10-K filed Feb 17, 2026, compared with Feb 13, 2025 /Numbers from the XBRL of the 10-Ks
Health care peers:
DVALHREGNVTRSIQVUHS
NYSE Health care · Research Services

IQVIA IQV

IQV quote by TradingView

IQVIA is a leading global provider of clinical research services, commercial insights and healthcare intelligence to the life sciences and healthcare industries. 10-K, Item 1

Headquarters
Durham, NC
CEO
Ari Bousbib
Next results
around Feb 4, 2027
Compare with peers Embed

IQV among Health care peers

Six ratios from the latest 10-K. Each corner is the share of 59 peers the company is above, not a score.

Compare
Revenue growth: 5.9%, above 39% of 59 peers (their median 7.2%) REVENUE GROWTH 5.9% · above 39% Operating margin: 12.8%, above 44% of 50 peers (their median 13.7%) OPERATING MARGIN 12.8% · above 44% Net margin: 8.1%, above 42% of 59 peers (their median 9.7%) NET MARGIN 8.1% · above 42% FCF margin: 12.0%, above 38% of 55 peers (their median 15.8%) FCF MARGIN 12.0% · above 38% Return on capital: 8.1%, above 37% of 41 peers (their median 9.2%) RETURN ON CAPITAL 8.1% · above 37%
IQV Peer median Below the median

What changed

7 new risk paragraphs. 10-K filed Feb 17, 2026 against Feb 13, 2025.

Risk factors
7 new paragraphs, nothing like them in the previous 10-K
10-K Item 1A
Accounting checks
10 other checks clear
10-K · XBRL
Insiders
No open-market buys in the last 90 days
Form 4
Filings
3 in the last 30 days
EDGAR

Each row opens the detail with the quote and the filing. A row is a change worth reading, not a verdict.

Accounting checks

10 checks on the latest 10-K. Checks, not verdicts.

How it works

0facts worth reading about all 10 checks found nothing to note

  • Receivables +6.1% vs revenue +5.9% (+0.2 pts)
  • Cash from operations $2.7B vs net income $1.4B (FY ending Dec 31, 2025)
  • Same auditor in both 10-Ks: PricewaterhouseCoopers LLP
7 more checks with nothing to note
  • No statement of substantial doubt about going concern
  • No 8-K item 4.02 in the last 2 years
  • No NT 10-K or NT 10-Q in the last 2 years
  • The same matters as last year: Revenue Recognition - Estimating Costs to Complete for Clinical Research Services
  • No sentence in the 10-K concludes that controls were not effective because of a material weakness
  • No 8-K item 2.06 in the last 2 years
  • No 8-K item 1.03 in the last 2 years

In their words

7 paragraphs in Risk Factors that were not in the 10-K filed Feb 13, 2025. Quoted as filed.

All 7 new paragraphs
  1. Item 1A · new paragraph · not in the 10-K filed Feb 13, 2025 10-K, ITEM 1A
    The confidentiality, collection, use, retention, security, transfer and disclosure of personal information is subject to governmental regulation in the countries where the personal information was collected or processed.
  2. Item 1A · new paragraph · not in the 10-K filed Feb 13, 2025 10-K, ITEM 1A
    Under most laws and regulations around the world, any information that relates to an identifiable natural person is considered “personal information”. In general, health information related to an identifiable person is considered “sensitive personal information” and is highly regulated. Processing health information carries additional…
  3. Item 1A · new paragraph · not in the 10-K filed Feb 13, 2025 10-K, ITEM 1A
    We are subject to rapidly changing and varied expectations and requirements on sustainability-related issues, from a wide range of stakeholders, such as governmental and self-regulatory organizations, including the Securities and Exchange Commission, U.S. federal and state governments, New York Stock Exchange, and the European Union, as…

New risk paragraphs, against peers

Latest 10-K of each, Health care companies closest in revenue

Paragraphs in Risk Factors with nothing like them in the company's 10-K the year before. A count of text, not of risk.

Financial performance

Last 4 fiscal years · 10-K XBRL

All years
MetricFY2022FY2023FY2024FY2025
Revenue$14.4B$15.0B$15.4B$16.3B
Net income$1.1B$1.4B$1.4B$1.4B
Operating cash flow$2.3B$2.1B$2.7B$2.7B
Free cash flow$1.6B$1.5B$2.1B$2.1B

Revenue, FY2016 to FY2025

Ten fiscal years, each from its own 10-K · XBRL · USD

$16.3B ▲ 5.9% in FY2025

FY2016FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025
Every number, year by year

Recent filings

3 filings in the last 30 days · SEC EDGAR

All filings

About the company

IQVIA, Durham, NC · from the 10-K filed Feb 17, 2026

IQVIA is a leading global provider of clinical research services, commercial insights and healthcare intelligence to the life sciences and healthcare industries. IQVIA’s portfolio of solutions are powered by IQVIA Connected Intelligence™ to deliver actionable insights and services built on high-quality health data, Healthcare-grade AI®, advanced analytics, the latest technologies and extensive domain expertise.

Headquarters
Durham, NC
Country
United States
Reports in
USD
Listed on
NYSE
Fiscal year ends
December 31
Last results
Oct 27, 2026
Incorporated in
DE

Email alerts

Sources

The 10-K filed Feb 17, 2026 (open at SEC), compared with the 10-K filed Feb 13, 2025. Numbers from the XBRL of the 10-Ks; filings from SEC EDGAR.

Work with it: Excel workbook · CSV. Google Sheet that stays up to date: paste =IMPORTDATA("https://tickdelta.com/company/IQV/export.csv") into a cell.